AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 62 min read$NTRA

Chapman Steven Leonard sold $774K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,409 shares of Natera, Inc. (NTRA) at $226.97 ($0.77M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not, by itself, provide new business performance or forward-looking guidance.

02

Market read

Primarily sentiment/positioning noise; limited fundamental read-through due to 10b5-1 pre-arrangement.

03

What to watch

Traders may overweight insider selling; the key mitigating detail is the pre-arranged 10b5-1 plan, which often reduces signal strength.

Relevance 6/10Novelty 3/10Timing: Filed June 5 for a June 4 sale; disclosure may affect intraday sentiment.

Background

SEC Form 4 insider transaction: CEO/president Chapman Steven Leonard sold 3,409 NTRA shares at ~$226.97 on June 4, with a stated 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $773.7K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Near-term price reaction likely muted; any move would be more sentiment/positioning-driven than fundamentals.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly references a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    Subject of the Form 4 insider sale by its CEO/president under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min